We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Capsaicin Shown to Be Potent Anticancer Agent

By Biotechdaily staff writers
Posted on 20 Apr 2006
The hot ingredient in red chili pepper, called capsaicin, has cancer-fighting properties that prevent or slow the growth of pancreatic cancer tumors implanted in mice, according to a new study.

Researchers at the University of Pittsburgh School of Medicine (PA, USA) found that capsaicin fed orally to mice with human pancreatic tumors caused the cancer cells to die through apoptosis. More...
Their findings were presented at the annual meeting of the American Association for Cancer Research in Washington (DC, USA) in April 2006.

Lead investigator Dr. Sanjay K. Srivastava, Ph.D., and colleagues fed mice grafted with human pancreatic tumors different amounts of capsaicin for five days per week or three days per week, according to their weight, then compared tumor size and levels of apoptotic proteins in the tumors to those in a control group of mice that received normal saline only. They found that the mice that received the capsaicin had increased levels of proteins associated with apoptosis and significantly smaller tumors sizes than the control group. Tumors treated with capsaicin were half the size of tumors in nontreated mice. Further testing revealed that capsaicin disrupted the mitochondrial function, which resulted in the release of several apoptotic proteins but it did not negatively affect normal pancreatic cells.

"Our results demonstrate that capsaicin is a potent anticancer agent, induces apoptosis in cancer cells and produces no significant damage to normal pancreatic cells, indicating its potential use as a novel agent for the prevention and treatment of pancreatic cancer,” said Dr. Srivastava.



Related Links:
U. of Pittsburgh

Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
New
Gold Member
Automatic Hematology Analyzer
CF9600
New
Thyroid Test
Anti-Thyroid EIA Test
New
Creatinine/eGFR Meter
StatSensor® Creatinine/eGFR Meter
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image

Urine-Based Multi-Cancer Screening Test Receives FDA Breakthrough Device Designation

Early detection across multiple cancers remains a major unmet need in population screening. Non-invasive approaches that can be delivered at scale may broaden access and shift diagnoses to earlier stages.... Read more

Molecular Diagnostics

view channel
Image: The new approach focuses on CpG DNA methylation, a chemical modification of cytosine and guanine bases, using tumor samples to develop a computational model that distinguishes among 21 cancer types (photo credet: 123RF)

Machine Learning Model Uses DNA Methylation to Predict Tumor Origin in Cancers of Unknown Primary

Cancers of unknown primary (CUP) are metastatic malignancies in which the primary site cannot be identified, complicating treatment selection. Many patients consequently receive broad, nonspecific chemotherapy... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.